Pharmaceuticals News and Research

RSS

EMD Millipore inaugurates new Shanghai Biopharmaceutical Technical Center

EMD Millipore, the Life Science division of Merck KGaA of Germany, today opened its state-of-the-art Biopharmaceutical Technical and Training Center in Shanghai, China. The 28,000 square foot facility will provide support, training and validation services to EMD Millipore's biopharmaceutical customers with operations in China.

11 May 2011

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.

11 May 2011

Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference

Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 21st European Congress of Clinical Microbiology and Infectious Diseases conference in Milan, Italy highlighting additional analyses of the Phase 3 data of DIFICID for the treatment of Clostridium difficile infection.

11 May 2011

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Sosei Group Corporation, the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc (miconazole Lauriad) in Japan from BioAlliance Pharma.

11 May 2011

NCL launches new public education campaign on medication adherence

Today the National Consumers League launches a new public education campaign, Script Your Future, to raise awareness among patients about the consequences of not taking medication as directed.

11 May 2011

China Sky One Medical first quarter total revenue decreases 1.9% to $28.4 million

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company in the People's Republic of China, today announced financial results for the first quarter of 2011.

11 May 2011

Micromet first quarter total revenues decrease to $5.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the first quarter ended March 31, 2011.

10 May 2011

AOBO's ZD Pill and CWJ Tablet receive Chinese approval for sales in Hong Kong

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced that the Company's Zhibai Dihuang Pill and Ciwujia Tablet have been approved for sale as traditional Chinese medicine in Hong Kong by Chinese Medicine Council of Hong Kong.

10 May 2011

Insmed first quarter revenues decrease to $1.6 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the first quarter ended March 31, 2011.

10 May 2011

Simcere first quarter total revenue increases 5.1% to RMB482.2 million

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today reported unaudited financial results for the first quarter ended March 31, 2011.

10 May 2011

Inspire reports net loss of $17.6 million for first quarter 2011

Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2011, reporting a net loss of $17.6 million or per common share, as compared to a net loss of $14.8 million, or per common share, for the same period in 2010.

10 May 2011

CorMedix first quarter net loss decreases to $1.9 million

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its financial results for the quarter ended March 31, 2011.

10 May 2011

Tetraphase presents TP-434, TP-2758 antibiotics study data against pathogens at ECCMID

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.

10 May 2011

Pepscan, Phylogica collaborate for Phylomer peptide lead optimisation

Phylogica Ltd, a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery.

10 May 2011

biocrea and Pfizer jointly presented details on novel PDE10 inhibitors

biocrea, a biopharmaceutical company focusing on novel treatments for disorders of the central nervous system (CNS), today reported details on the design and synthesis of novel, brain-penetrating phosphodiesterase-10 (PDE10) inhibitors developed in collaboration with Pfizer Inc. (NYSE: PFE). The data were featured in joint presentations1 with Pfizer at the recent 241st ACS National Meeting & Exposition, an event organized by the American Chemical Society (ACS).

10 May 2011

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite at least imatinib and sunitinib as prior treatments.

10 May 2011

OncoGenex first quarter revenue decreases to $1.2 million

OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.

10 May 2011

Scientists decipher genome of tropical marine organism

An international team of researchers led by scientists at Scripps Institution of Oceanography at UC San Diego has deciphered the genome of a tropical marine organism known to produce substances potentially useful against human diseases.

10 May 2011

UCSF scientists receive CIRM grants to advance degenerative muscle disease research

Three UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their investigations of treatment strategies for degenerative muscle diseases, such as muscular dystrophy, and heart disease, and to determine why human embryonic stem cells are susceptible to forming tumors.

10 May 2011

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661.

10 May 2011